title: Absorption and bioavailability of oral transmucosal fentanyl citrate.
abstract: Oral transmucosal fentanyl citrate (OTFC) is a novel, noninvasive dosage form of fentanyl used to provide children and adults with sedation, anxiolysis, and analgesia. In order to determine the bioavailability and absorption of fentanyl from OTFC, 12 volunteers were given intravenous fentanyl citrate or OTFC 15 micrograms/kg on each of two occasions. On a third occasion, the authors assessed oral administration (gastrointestinal absorption) by giving eight of the same volunteers the same dose of a solution of fentanyl citrate to swallow. In each study, arterial blood samples were taken over 24 h for analysis of plasma fentanyl. After intravenous (iv) administration of fentanyl, clearance (mean +/- standard deviation) was 0.67 +/- 0.15 l/min; volume of distribution at steady state was 287 +/- 79 l; and the terminal elimination half-life was 425 +/- 102 min. Peak plasma concentrations of fentanyl were higher (3.0 +/- 1.0 vs. 1.6 +/- 0.6 ng/ml, P = 0.01) and occurred sooner (22 +/- 2.5 vs. 101 +/- 48.8 min, P = 0.003) after OTFC than after oral solution administration. Plasma concentrations of fentanyl after OTFC decreased rapidly, to less than 1.0 ng/ml within 75-135 min after the beginning of administration. Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001). Systemic bioavailability was greater after OTFC administration than after the oral solution (0.52 +/- 0.1 vs. 0.32 +/- 0.1, P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City 84132.
authors.forename: J B
authors.initials: JB
authors.lastname: Streisand
authors.forename: J R
authors.initials: JR
authors.lastname: Varvel
authors.forename: D R
authors.initials: DR
authors.lastname: Stanski
authors.forename: L
authors.initials: L
authors.lastname: Le Maire
authors.forename: M A
authors.initials: MA
authors.lastname: Ashburn
authors.forename: B I
authors.initials: BI
authors.lastname: Hague
authors.forename: S D
authors.initials: SD
authors.lastname: Tarver
authors.forename: T H
authors.initials: TH
authors.lastname: Stanley
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D005283:Fentanyl / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D007408:Intestinal Absorption; D008297:Male; D009061:Mouth Mucosa / Q000378:metabolism*; D011897:Random Allocation
chemical_list: D005283:Fentanyl